Literature DB >> 20639829

Contrast induced nephropathy in diabetic and non-diabetic patients during coronary angiogram and angioplasty.

M M Rahman1, H S Haque, S K Banerjee, S A Ahsan, M F Rahman, M Mahmood, M Salman, M G Azam.   

Abstract

This study was done to assess the incidence of contrast-induced nephropathy (CIN) after coronary angiogram (CAG) and percutaneous transluminal coronary angioplasty (PTCA). Contrast induced nephropathy is the third leading cause of acute renal failure in hospitalized patients. Diabetes mellitus, volume depletion, baseline renal insufficiency, and high volume of contrast agent are a few risk factors. In 245 consecutive patients undergoing CAG or PTCA, we measured serum creatinine at baseline and after 24 and 48 hours of the procedure. CIN was defined as rise in serum creatinine >/=0.5mg/dL or 25% rise from baseline. Two hundred twenty three (91%) subjects were male and 22(9%) were female. Among the 245 subjects 155 (63.3%) were diabetic. Total 59(24.08%) patients developed contrast induced nephropathy. Among these patients, 57(36.8%) were diabetic whereas only 2(2.2%) were non-diabetic. In 59 CIN cases 57(96.6%) were diabetic (p</=0.0001). Among total 59 CIN cases, more than 100 ml of contrast agent used in 51(86.4%) patients (p</=0.0001). Diabetic patients are more prone to develop CIN than non-diabetic. Volume of contrast agent used during procedure is an important predictor for the development of CIN.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20639829

Source DB:  PubMed          Journal:  Mymensingh Med J        ISSN: 1022-4742


  1 in total

1.  Evaluation of coenzyme Q10 combined with or without N-acetyl cysteine or atorvastatin for preventing contrast-induced kidney injury in diabetic rats.

Authors:  Osama Y Alshogran; Shreen D Nusair; Tamam El-Elimat; Karem H Alzoubi; Abdullah Obeidat; Maya Sweidan
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2021-02-25       Impact factor: 3.000

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.